11:02 AM EDT, 09/02/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) , up 1% on last look, on Tuesday announced additional positive clinical data from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE). It noted patients treated with 4mg per injection of EP-104GI had "meaningful" levels of clinical remission at Week 12, right up to Week 52.

The company said that at 12 months, two-thirds of Cohort 5 patients remained in clinical remission after their treatment with EP-104GI. No serious adverse events have been reported to date in the entire trial.

"We believe the prolonged duration of symptom response that we are seeing with EP-104GI is truly a unique clinical result and will potentially provide a once-a-year therapy to patients with EoE. And overall, we continue to see that the more drug we deliver to the tissues, the better the results," said Dr. James A. Helliwell, chief executive officer.

Eupraxia plans to release additional data from the RESOLVE trial during the third quarter of this year.

The company's shares are up $0.07, to $7.49, on the Toronto Stock Exchange.

Price: 7.49, Change: +0.07, Percent Change: +0.94